title: Hypofractionated stereotactic radiotherapy for low grade glioma at McGill University: long-term follow-up.
abstract: Small, well-defined, unresectable low-grade gliomas are attractive targets for stereotactic irradiation. Fractionated stereotactic irradiation of these targets has the theoretical benefit of increased normal tissue sparing beyond that provided by the physical characteristics of stereotactic radiosurgery. From July 1987 to November 1992, 21 patients were treated for low-grade glioma at our institution using a hypofractionated regimen of stereotactic radiotherapy. All patients had well-circumscribed, < 40 mm tumors. No patient had had prior radiotherapy. All lesions were histologically proven WHO grade I or II glial tumors. Lesions involved sensitive brain structures and were deemed unresectable. A typical dose of 42 Gy was delivered in 6 fractions over a two-week period using rigid immobilization and a linac-based dynamic stereotactic radiosurgical technique. Patients had a median age of 23 years (9-74) and were predominantly female (60%). Median tumor diameter was 20 mm. With a median follow-up for living patients of 13.3 years, the actuarial 5, 10, and 15-year overall survival rates are 76%, 71%, and 63%, respectively. Treatment was acutely well tolerated although three patients experienced late post-therapy complications. Our results and those of 241 patients treated in nine other institutional series are reviewed. Despite some examples of favorable short-term outcomes, all reported series are highly selected and thus likely biased. The data regarding the use of SRS is limited and, in our opinion, insufficient to claim a clear therapeutic advantage to SRS in the initial management of low-grade glioma. Our own results with hypofractionated stereotactic radiotherapy are similar to those expected with standard therapy.
authors.affiliation: Department of Oncology, Division of Radiation Oncology, McGill University Heath Center, Montreal General Hospital, 1650 Cedar Av., Room D5.400, Montreal, QC H3G 1A4, Canada. david.roberge@muhc.mcgill.ca
authors.forename: D
authors.initials: D
authors.lastname: Roberge
authors.forename: L
authors.initials: L
authors.lastname: Souhami
authors.forename: A
authors.initials: A
authors.lastname: Olivier
authors.forename: R
authors.initials: R
authors.lastname: Leblanc
authors.forename: E
authors.initials: E
authors.lastname: Podgorsak
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000401:mortality / Q000601:surgery*; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000401:mortality / Q000601:surgery*; D006785:Hospitals, University; D006801:Humans; D008297:Male; D008875:Middle Aged; D011792:Quebec; D016634:Radiosurgery; D015996:Survival Rate; D016896:Treatment Outcome